The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

Diabetes Care

Volumn 20, Issue 5, 1997, Pages 687-691

  Segal, P ^a   Feig, P U ^b   Schernthaner, G ^c   Ratzmann, K P ^d   Rybka, J ^e   Petzinna, D ^f   Berlin, C ^f  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAYER CORPORATION   (United States)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^d Schlossklinik Dahme   (Germany)

^e Bata Hospital   (Czech Republic)

^f BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; MIGLITOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FLATULENCE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 0030972122     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.5.687     Document Type: Article

References (20)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
3. Lasker RD: The Diabetes Control and Complications Trial: implications for policy and practice. N Engl J Med 329:1035-1036, 1993
4. Colwell JA: DCCT findings: applicability and implications for NIDDM. Diabetes Rev 2:277-291, 1994
5. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly-diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
6. Stout RW: Insulin and atheroma. Diabetes Care 13:631-654, 1990
7. Caspary WF: Sucrose-malabsorption in man after ingestion of α-glucosidehydrolase inhibitor. Lancet i:1231-1233, 1978
8. Lembcke B, Folsch UR, Creutzfeldt W: Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Digestion 31:120-127, 1985
9. Reuser AJJ, Wisselaar HA: An evaluation of the potential side-effects of α-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 24 (Suppl. 3): 19-24, 1994
10. Kingma PJ, Menheere PPCA, Sels JP, Nieuwenhuijzen Kruseman AC: α-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 15:478-483, 1992
11. Joubert PH, Venter HL, Foukaridis GN: The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? Br J Clin Pharmacol 30:391-396, 1990
12. Sels JP, Kingma PJ, Wolffenbuttel BH, Menheere PP, Branolte JH, Nieuwenhuizen-Kruseman AC: Effect of miglitol (BAY m 1099) on fasting blood glucose in type 2 diabetes mellitus. Neth J Med 44:198-201, 1994
13. DeFronzo RA: The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
14. Kuusisto J, Mykkanen L, Pyörälä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
15. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fucker K: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
16. Tuomilehto J: Acarbose monotherapy in the treatment of non-insulin-dependent diabetes mellitus: a review. In Acarbose for the Treatment of Diabetes Mellitus. 2nd International Symposium on Acarbose. Creutzfeldt W, Ed. Berlin, Springer Verlag, 1988, p. 104-116
17. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A: Effect of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17:20-29, 1994
18. Dimitriadis G, Hatziagellaki E, Alexopoulos E, Kordonouri O, Komesidou V Ganotakis M, Raptis S: Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus. Diabetes Care 14:393-398, 1991
19. Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, Schernthaner G: Effects of 8-wk α-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12:537-543, 1989
20. Pagano G, Marena S, Corgiat-Mansin L, Cravero F, Giorda C, Bozza M, Rossi CM: Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabete Metab 21:162-167, 1995